01OverviewDefinition, clinical context and the essential points that orientate the chapter.
Gallbladder carcinoma is often biologically advanced before symptoms become specific. The thin wall, direct hepatic attachment and rich lymphatic drainage facilitate early extension into liver, porta-hepatis nodes, bile ducts and peritoneum. Right-upper-quadrant pain may resemble gallstone disease; progressive weight loss, a mass or jaundice raises later-stage concern. A polypoid lesion or irregular focal wall thickening on ultrasound needs deliberate characterisation.
An important route to diagnosis is incidental histology after laparoscopic cholecystectomy. Management then depends on pathological T stage, cystic-duct and liver-bed margins, differentiation, lymphovascular or perineural invasion, whether the specimen was opened, and whether bile spilled. These facts influence residual-disease risk and the design of completion surgery. Recutting slides at an experienced centre can change staging.
Curative treatment aims for R0 clearance and regional nodal staging in a fit patient without metastases. Completion radical surgery can add a margin-negative liver-bed wedge and nodes along the cystic/common ducts, hepatic arteries, portal vein and posterosuperior pancreatic head. Anatomical IVb/V resection depends on extent; a wedge is accepted for T1b/T2 disease. Advanced disease requires coordinated oncology and symptom treatment.
Key points
- Most gallbladder cancers are adenocarcinomas and may be discovered incidentally after cholecystectomy or during imaging for pain, weight loss or jaundice.
- Risk rises with chronic gallbladder inflammation, especially long-standing stones; porcelain gallbladder, large polyps and congenital biliary abnormalities alter concern but do not replace tissue diagnosis.
- Obtain staging-quality contrast CT of chest, abdomen and pelvis; MRI can clarify liver, hilar and bile-duct involvement when CT anatomy is incomplete.
- When malignancy is suspected before surgery, refer to an HPB MDT before routine cholecystectomy so the operation, possible en-bloc resection and staging are planned oncologically.
- For incidental disease, secure the full pathology report, original images and operation note, including perforation or bile spillage, margin status, depth, nodes and specimen handling.
- ESMO guidance supports completion surgery for sufficiently fit patients with incidental gallbladder carcinoma stage T1b or higher when staging shows no metastases; T1a confined to lamina propria is generally treated by complete cholecystectomy.
- After curative resection, discuss adjuvant capecitabine with specialist oncology; metastatic disease requires performance-status assessment, molecular profiling and symptom-focused biliary care.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
Chronic stone inflammation
Long-standing calculi and repeated mucosal injury are the dominant association, although most people with gallstones never develop gallbladder carcinoma.
Precursor mucosal lesions
Dysplasia, carcinoma in situ and intracholecystic papillary-tubular neoplasms can precede invasive adenocarcinoma through distinct pathological routes.
Structural risk states
Large polyps, porcelain gallbladder and anomalous pancreaticobiliary junction increase concern and should be interpreted with age, morphology and specialist imaging.
03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
- 1Transmural spread
A thin wall and absent serosa at the hepatic interface permit early direct invasion into segments IVb and V.
- 2Lymphatic dissemination
Drainage through cystic and pericholedochal nodes allows porta-hepatis and more distant nodal spread before a large primary mass develops.
- 3Peritoneal seeding
Serosal breach, spontaneous perforation or operative bile spillage can distribute malignant cells across the peritoneal cavity and port sites.
- 4Biliary invasion
Extension along the cystic duct or into the hilum obstructs hepatic ducts, causing segmental cholestasis, jaundice and recurrent infection.
04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
Cancer unexpectedly reported after cholecystectomy requires the stage, margins, high-risk histology and operative events before a completion plan can be made.
A discrete mass replacing the gallbladder, asymmetric irregular thickening, liver invasion or nodes differs from uncomplicated diffuse inflammatory wall oedema.
Jaundice may result from direct hilar invasion or nodal compression and often signals complex local anatomy rather than an isolated gallbladder lesion.
Ascites, peritoneal nodules, liver metastases or distant nodes can make radical resection futile and redirect care toward systemic and symptom treatment.
Fever, rigors, hypotension or a tender obstructed gallbladder demands acute source-control assessment alongside the malignancy pathway.
05InvestigationsWhat to request, why it matters and how to interpret it.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Specialist pathology reviewFirst step - Why
- Confirm histological type, depth, margins and adverse features after incidental discovery.
- Interpretation and limitations
- Separate T1a lamina-propria invasion from T1b muscular invasion and deeper disease; report cystic-duct margin, liver interface, nodes, differentiation and vascular or neural invasion.
- 02
Contrast CT chest, abdomen and pelvis - Why
- Stage liver invasion, vascular contact, regional nodes, peritoneum, lungs and distant disease before radical treatment.
- Interpretation and limitations
- Absence of visible metastasis permits but does not guarantee resectability; subtle peritoneal spread may remain occult and is considered in operative planning.
- 03
Liver MRI and MRCP - Why
- Resolve equivocal liver lesions and define hilar or duct involvement when this changes the resection or drainage strategy.
- Interpretation and limitations
- Segmental duct obstruction and vascular anatomy must be read together; instrumentation before mapping can complicate interpretation.
- 04
Baseline liver, renal and coagulation tests - Why
- Measure obstruction and organ reserve before contrast, surgery, drainage or systemic therapy.
- Interpretation and limitations
- Correct reversible dehydration and vitamin K-related coagulopathy, but recognise that jaundice from extensive hilar disease may not normalise with a single drain.
- 05
CA19-9 and CEA - Why
- Provide adjunctive baseline tumour markers for selected patients after imaging.
- Interpretation and limitations
- Obstruction and inflammation can elevate markers, Lewis-antigen non-secretors may not produce CA19-9, and neither test diagnoses gallbladder cancer alone.
- 06
Staging laparoscopy when selected - Why
- Detect small peritoneal or superficial liver metastases before committing to a large open resection.
- Interpretation and limitations
- Use according to specialist assessment of T stage and dissemination risk; positive cytology or implants change a curative operative plan.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
Acute cholecystitis
Diffuse oedematous thickening with stones and acute tenderness may mimic tumour, but focal irregular tissue and invasion demand specialist review.
Gallbladder adenomyomatosis
Benign intramural sinuses and characteristic imaging artefact can resemble wall thickening, especially when the examination is technically limited.
Xanthogranulomatous inflammation
Destructive chronic inflammation may invade adjacent liver and imitate advanced carcinoma radiologically and during operative assessment.
Hilar cholangiocarcinoma
A primary bile-duct tumour can invade the gallbladder or appear as hilar obstruction; duct-centred imaging and pathology distinguish origin.
07ManagementImmediate care, first-line treatment, alternatives and escalation.
01Incidental T1aConfirm whether cholecystectomy was completeFirst stepHistology shows adenocarcinoma confined to lamina propria with clear cystic-duct and liver-bed margins.+
- 1Request specialist pathology confirmation of T1a depth and verify an intact specimen and clear margins.
- 2Review staging imaging and operative documentation for unexpected disease, perforation or dissemination.
- 3If complete T1a resection is confirmed, no radical completion liver resection is usually required.
- 4Give an explicit surveillance and symptom plan through the HPB team rather than losing the incidental result between services.
02Worked case: incidental T1b completion surgeryStage before completion surgeryA fit 62-year-old has incidentally discovered gallbladder adenocarcinoma invading the muscular layer, clear cystic-duct margin and no metastases on staging CT after uncomplicated cholecystectomy.+
- 1Specialist pathology review confirms T1b muscular invasion and the clear cystic-duct margin; the operation record documents an intact specimen without bile spillage.
- 2The HPB team confirms adequate operative fitness and no radiological metastatic disease, then discusses the residual-disease risk and potential benefit and morbidity of completion surgery.
- 3The patient accepts completion liver-bed wedge resection with the regional lymphadenectomy described above. The plan seeks negative margins; a larger anatomical liver resection is reserved for anatomy requiring it.
- 4Completion pathology shows clear margins and no involved regional nodes. At the six-week postoperative review the wound has healed and functional recovery is satisfactory. After discussing the uncertainty of adjuvant benefit and capecitabine toxicity with oncology, the patient chooses surveillance; the team records that informed decision and supplies the agreed follow-up and symptom-contact plan.
03Suspected before operationAvoid an unplanned simple excisionUltrasound and CT show a focal gallbladder mass invading the adjacent liver.+
- 1Refer directly to an HPB cancer MDT with staging images rather than listing for routine gallstone surgery.
- 2Assess distant and peritoneal disease and determine whether tissue is necessary before treatment.
- 3Plan an en-bloc R0 operation with regional nodal staging if resectable and physiologically appropriate.
- 4If unresectable, obtain diagnosis by the safest route and integrate oncology with obstruction, pain and nutritional care.
Key medicines and prescribing safety1 treatment · regimens, roles and cautions+
Adjuvant capecitabine after resected biliary tract cancer: specialist BILCAP-derived schedule
For specialist guideline-supported off-label adjuvant biliary use after recovery from resection, the BILCAP-derived schedule is capecitabine 1,250 mg/m² orally twice daily on days 1–14 of each 21-day cycle for eight cycles, approximately six months. Take morning and evening doses within 30 minutes after food; swallow tablets whole with water, without crushing or cutting. Oncology calculates and rounds the body-surface-area dose to available strengths and applies toxicity holds/reductions.Test DPD before treatment: complete deficiency is contraindicated and partial deficiency needs a reduced specialist starting strategy. Exclude severe hepatic impairment, severe cytopenias, previous severe unexpected fluoropyrimidine reactions and product hypersensitivity. Do not start if neutrophils are below 1.5 × 10⁹/L or platelets below 100 × 10⁹/L; interrupt if on-treatment counts fall below 1.0 or 75 × 10⁹/L respectively. At Cockcroft–Gault CrCl 30–50 mL/min reduce the 1,250 mg/m² starting dose to 75%; below 30 do not start, and discontinue if it falls below 30 during treatment. Allow at least four weeks after stopping brivudine before capecitabine. Monitor INR/PT closely with warfarin and adjust anticoagulation; avoid allopurinol and monitor phenytoin concentrations/toxicity. Pregnancy is contraindicated; effective contraception continues for six months after the last dose for women and three months for men with partners of reproductive potential. Stop breastfeeding during treatment and for two weeks afterwards. Check FBC, renal/hepatic function and toxicity before each cycle. Stop and contact oncology for diarrhoea, stomatitis, fever, chest pain, dehydration or painful hand-foot reaction.
08ComplicationsImportant consequences, why they occur and why they matter clinically.
Hilar obstruction
Local extension can isolate hepatic sectors, causing jaundice, pruritus and cholangitis that require carefully targeted drainage.
Liver invasion
Direct hepatic spread increases the extent of resection needed for a clear margin and may involve portal structures.
Peritoneal metastasis
Small implants can evade CT, produce ascites or obstruction, and render an intended radical operation non-curative.
Treatment toxicity
Major HPB surgery and fluoropyrimidine therapy can cause nutritional decline, infection, diarrhoea, cytopenia and functional loss requiring active monitoring.
09Monitoring and follow-upTreatment response, safety checks and longer-term review.
- After incidental diagnosis, use a tracked referral so pathology review, staging CT and the completion-surgery decision occur without administrative delay.
- Before each capecitabine cycle, specialist protocols review full blood count, renal and hepatic function, performance status, diarrhoea, mucositis and hand-foot toxicity.
- After resection, review final margins and nodal yield at the MDT because these findings shape adjuvant and radiotherapy discussion.
- During surveillance, new pain, weight loss, jaundice or declining function warrants earlier imaging rather than waiting for a routine date.
- For a biliary stent, monitor fever, recurrent itch, dark urine and bilirubin trend and give a named urgent contact for suspected occlusion.
10Special situationsVariants, exceptions and circumstances that change the usual approach.
The operation note is staging evidence
Perforation, bile spillage, specimen retrieval and visualised peritoneal disease influence the risk assessment after an incidental cancer diagnosis.
Depth changes the next operation
T1a and T1b lie only one tissue layer apart, yet muscular invasion generally triggers consideration of oncological completion surgery.
Jaundice suggests complex disease
Hilar invasion or porta-hepatis nodes can separate duct systems and require segment-specific decompression rather than a routine distal stent.
Inflammation can mimic invasion
Acute cholecystitis creates wall thickening and adjacent hepatic change, so expert radiology and pathology correlation prevent over- or understaging.
Markers follow rather than diagnose
CA19-9 and CEA can support a baseline but obstruction, infection and secretor status limit their standalone meaning.
11Common pitfallsFrequent interpretation and management errors.
- 01
Performing routine laparoscopic cholecystectomy on a radiologically suspicious mass can breach tumour and miss the required oncological resection.
- 02
Treating every incidental cancer as cured by the original operation ignores residual risk from T1b or deeper invasion.
- 03
Offering radical completion surgery before staging can expose a patient with metastatic disease to morbidity without curative benefit.
- 04
Starting capecitabine without DPD and renal assessment risks severe avoidable fluoropyrimidine toxicity.
- 05
Using a high CA19-9 during obstruction as proof of metastasis can deny potentially curative assessment.